article thumbnail

FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS

Pharmaceutical Technology

Bylvay is a once-a-day, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure. The therapy is being offered immediately through prescription for eligible ALGS patients. More than 90% of patients who received treatment with odevixibat were pruritus responders.

article thumbnail

Addressing the Polypharmacy Problem

PM360

If one of those conditions is type 2 diabetes, that person may be taking seven prescription medications, 1 managing two or more additional chronic conditions, 2 and paying $13,000 per year on healthcare. senior adults (aged 65+) 7 taking five or more prescription medications. 3 They are also 2.6 In the U.S., 5 This links to 22% of U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

News release: Clarify Health unlocks greater clinical trial diversity with launch of Clarify Trials

Clarify Health

Clarify Trials’ analytics draws upon a dataset that includes patient-level SDoH data across an extensive set of factors, such as gender, race, ethnicity, income level, transportation access, housing stability, education level and health literacy.

article thumbnail

And so pharma profiteers again

World of DTC Marketing

8 spot ahead of industries such as retail, transportation, and media, and entertainment. BMS believes they price our medicines based on the value they deliver,” but physicians say the price is too high. Best of all are patients in the US, where prices are highest, and with chronic conditions requiring repeat prescriptions.

Pharma 191
article thumbnail

Clinical Research News: Social Determinants Of Health Data Help Identify Sites For Trials

Clarify Health

It has been more than a decade now since the notion of social determinants started expanding to consider access to transportation, food, income, and decent housing on care journeys and outcomes, says Drouin. Switzerland Platform’ .

article thumbnail

Two Key Questions About Adherence/Compliance in 2023

PM360

These discussions can be initiated by HCPs ranging from physicians to advanced practice professionals. What if the industry were to incentivize persistence over new prescriptions? Facilitating this level of communication can foster concordance and ultimately drive desirable clinical outcomes.

Medical 98
article thumbnail

Clinical Research News: Social Determinants Of Health Data Help Identify Sites For Trials

Clarify Health

It has been more than a decade now since the notion of social determinants started expanding to consider access to transportation, food, income, and decent housing on care journeys and outcomes, says Drouin.